The Securities and Exchange Commission established the fund after finding that Becton, Dickinson and Company failed to disclose significant regulatory and financial risks tied to the Alaris device. On February 6, 2020, the company disclosed it needed new FDA clearance for the pump and would halt sales, triggering a 12% drop in share price. While the firm settled the charges without admitting or denying the findings, it was ordered to pay a $175 million civil penalty to compensate affected shareholders.
In section Releases
Investors Eligible for Share of $175 Million Becton Fair Fund
Investors who held Becton, Dickinson and Company stock between February 5, 2019, and February 5, 2020, are now eligible to file claims for a $175 million settlement. The fund follows an SEC investigation into the company's misrepresentations regarding risks associated with its Alaris infusion pump.
To participate, claimants must submit documentation to JND Legal Administration by December 13, 2026. Forms are available at www.BectonFairFund.com, where electronic submissions are encouraged. Brokers and other nominees holding records for beneficial owners are required to provide notification or contact details to the administrator within 14 days of receiving notice. Further inquiries can be directed to the administrator at (866) 910-1105.
Comments (0)
No comments yet. Be the first!